You Are Leaving Avistone's Website
You have selected a link that will take you to a site maintained by a third party. Avistone provides this link as a service to website visitors. Avistone is not responsible for the privacy policy of any third party websites. We encourage you to read the privacy policy of every website you visit. Click 'Cancel' to return to Avistone's site or 'Continue' to proceed.
-
2025
04-16
Avistone Announces Preclinical Results for ANS03, a Novel Type II ROS1/NTRK Inhibitor in Overcoming Clinically Relevant ROS1/NTRK Resistance Mutations at AACR Annual Meeting 2025
BEIJING--(BUSINESS WIRE)--Beijing Avistone Biotechnology Co., Ltd.(“Avistone”), an innovative biotechnology company focused on precision oncology therapeutics, today announced that the preclinical data for ANS03, its novel, orally bioavailable Type II ROS1/NTRK tyrosine kinase inhibitor (TKI), will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025.
View Details
-
2024
12-25
Vebreltinib's Third Indication for NSCLC with MET Amplification was Officially Accepted by China CDE and Granted as Priority Review
On December 25, 2024, Avistone announced that its wholly-owned subsidiary, Beijing Pearl Biotechnology Co., Ltd., submitted a New Drug Application (NDA) to the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) for a new indication of Vebreltinib (PLB-1001). This application has been officially accepted by CDE and granted as priority review. The proposed indication is for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with MET amplification. This milestone indicates that the field of NSCLC with MET Amplification is expected to enter a new era of precision-targeted therapy.
View Details
-
2024
11-28
Two Indications of Vebreltinib Included in the China 2024 National Reimbursement Drug List
In the newly released National Reimbursement Drug List (NRDL) for Basic Medical Insurance, Work-Related Injury Insurance, and Maternity Insurance (2024), Vebreltinib, a novel MET inhibitor developed by Pearl Biotechnology, a wholly-owned subsidiary of Avistone has been successfully included.
View Details
